Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

News Briefs: Biomet IPO; Hep C Screening Coverage; Valve Guidelines

This article was originally published in The Gray Sheet

Executive Summary

Biomet’s parent company filed an initial public offering registration statement for the firm March 7. CMS proposes national coverage for hepatitis C screening. ACC and AHA release new heart valve guidelines. More news.

You may also be interested in...



Allergan To Sell Lap-Band Franchise To Apollo For Up To $110 Million

The firm announced Oct. 29 an agreement with Apollo Endosurgery to sell its obesity intervention business, including the Lap-Band adjustable band.

Reimbursement Briefs: National Coverage Updates; MolDx Meeting Request; Sleep Study Questions

Hepatitis C virus screening national coverage supported in comments. Proposed decision memo delayed for percutaneous image-guided lumbar decompression for lumbar spinal stenosis national coverage determination. More reimbursement news.

Bridge Too Far? BMS Launch Plan For Sotyktu Pressured By Prospect Of Medicare Price Controls

With price controls in Medicare looming nine years after approval, launch strategies such as ‘bridge’ programs that build initial volume with free drug may have to be adjusted.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT032804

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel